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Abstract 
 
Purpose of the review: The purpose is to describe the most recent literature associated with HIV self 
–testing (HIVST).  
 
Recent findings: HIVST is acceptable to a range of populations in a variety of contexts, particularly if 
users values and preferences are taken into account in intervention development. Approaches being 
explored in on-going and planned studies are the efficacy of HIVST to increase diagnosis of 
longstanding prevalent infections and to reduce the interval between HIV transmission and 
diagnosis, particularly in high incidence groups. Though there is little evidence of harms related to 
HIVST, this remains a potential issue. Concerns remain about the reliability of currently available 
HIVST kits, which have lower sensitivity than testing options available in clinical settings, particularly 
in early HIV infection. Evidence on linkage to care for confirmatory testing after a reactive HIVST 
result and the cost effectiveness of HIVST to increase rates of HIV diagnosis is currently limited.  
 
Summary: HIVST is  relatively new innovation that appears acceptible to key populations and which 
could increase HIV testing rates and rates of HIV diagnosis especially in at-risk groups. Concerns 
remain about test sensitivity, particularly in early HIV infection, and linkages to care for confirmatory 
testing after a reactive HIVST.   
 
  
Scope of this review  
The field of literature surrounding HIVST is evolving rapidly. While some key literature has been 
formally published, much of the most up to date and relevant evidence comes from conference 
abstracts.  Understanding key elements of HIVST, including values and preferences in key 
populations most impacted by HIV is crucial. In terms of HIVST outcomes; feasibility studies, pilot 
HIVST projects and non-RCT intervention studies have occurred in a variety of settings, as have 
several randomised controlled trials (RCTs). Both RCTs and non-RCTs typically focus on interventions 
to detect prevalent infections, or increase testing frequency. Evidence on harm is limited, but 
important work is emerging. Economic evidence including cost-effectiveness analysis is very much in 
the nascent stages of development.  
The purpose of this review is to describe the most recent literature on outcomes and issues 
associated with HIVST.  
 
HIV testing rates 
A high proportion of people living globally with HIV remain undiagnosed. Despite intensive 
interventions to increase testing over the past decade, 17.1 million of the estimated 36.9 million 
people living with HIV worldwide in 2014 remained undiagnosed (1). This has implications not just 
for individual health, with the results of the START trial in 2015 indicating antiretroviral therapy 
(ART) is beneficial at any CD4 count, but also for onward transmission of HIV, with 60-80% of 
transmission thought to occur from those as yet undiagnosed and often in the early stages of 
infection where risk of onward transmission is greater (2-5).  
The ‘Test and Treat’ approach has been enshrined in the UNAIDS global 90-90-90 targets, which aim 
by 2020, to achieve 90% of people with HIV being diagnosed, 90% taking ART and 90% of those 
treated achieving virological suppression (6).  The first ‘90’ is the largest gap with only 53% of those 
living with HIV currently being diagnosed. Efforts to increase testing rates has led to expansion of 
testing opportunities and testing interventions to meet the needs of a range of different groups in a 
variety of contexts (see Table 1) (7-10). HIV self-testing (HIVST) is simply the latest iteration of 
testing modalities.   
 HIV self-testing  
 
Regulatory approval and policy 
We define HIVST as when an individual takes their own sample, processes it and interprets their own 
result. A reactive result from an HIVST is not a diagnosis; this requires the individual to subsequently 
attend a testing facility for confirmatory HIV testing and linkage to care. Self-tests for a variety of 
other conditions are already available to the general public. HIV has long been viewed as an 
exceptional disease by policy makers and clinicians, and this exceptionalism meant that early in the 
epidemic, HIVST was banned in many countries, due to concerns over the potential for self-harm in 
the absence of effective treatments and the potential for coercive use (11). In recent years, the shift 
in HIV to a chronic manageable disease with near normal life expectancy (12, 13) through highly 
effective ART has led to changing attitudes towards of the impact of HIV diagnosis among clinicians 
and populations affected by HIV. These changes have led to a more permissive policy environment, 
with increasing numbers of countries enacting laws or repealing legislation making rapid diagnostic 
tests (RDTs) for self use available. The UK for example legalised HIVST on April 1st 2014, with the first 
commercially available test released the following year (BiosureTM). HIVST is permitted with 
regulated tests available from the private sector in other countries such as the US, France, Belgium 
and Brazil (14). Other countries such as Australia have policies permitting HIVST, but no tests are as 
yet approved by the necessary regulatory agencies. Many more nations have no official policies on 
the technology, but unregulated HIVSTs and RDTs intended for clinical use are often available either 
online or through pharmacies, raising concerns about quality (14).  
In efforts to continue expanding HIV testing, HIVST has been officially adopted on a global policy 
level, with the World Health Organisation (WHO) incorporating HIVST into their Consolidated 
Guidelines on HIV testing services in July of 2015 (15).  
 
Potential benefits  
HIVST has been promoted as a low cost alternative to facility based testing, potentially reducing 
barriers such as stigma and opportunity cost while boosting patient choice and enhancing 
autonomy, thereby potentially expanding testing to new groups and enabling increased testing 
frequency in those at highest risk (16). HIVST also has applications in intensive combination HIV 
prevention initiatives such as the targeted expansion of testing, treatment and pre-exposure 
prophylaxis (PrEP) (16, 17). HIVSTs are available using both a whole blood sample, usually from a 
finger prick, or using oral fluid.  
 
Understanding implementation contexts: values and preferences  
In general studies, which seek to understand how populations might accept HIVST, tend to include 
participants who have not actually experienced HIVST themselves and the intervention is therefore 
hypothetical. Understanding this evidence remains worthwhile because it provides an indication of 
how populations are likely to engage with the technology, and how interventions should be 
delivered to ensure they are acceptable.  
MSM (and to a lesser extent trans gender women and female sex workers [FSW]) in high and middle 
income settings are well represented in literature around HIVST acceptability as well as values and 
preferences, though there is little data as yet from Europe. General populations are less well 
represented in available data, although there is some evidence emerging from East and Southern 
Africa (18, 19).  Recent studies report high acceptability for HIVST across a range of settings and 
populations. Emerging evidence from Peru (20, 21), Scotland (22), the USA (23, 24), Vietnam (25) 
and Mexico (26) report that MSM find HIVST highly acceptable, with moderate acceptability 
observed in Hong Kong (27). In a recent cross-sectional study in England, HIVST was the second most 
preferred location for future HIV testing and tended to have greater popularity amongst MSM less 
likely to test at a frequency in line with national guidelines (28).  
Confidentiality, convenience, immediacy and the opportunity to increase testing frequency are 
commonly cited benefits of HIVST (22-25, 29-32). Barriers tend to be concerns around dislocation 
from care pathways, the possibility of coercive testing practices, and perceived issues with self-
efficacy as well as kit accuracy (31, 33, 34).  
A systematic review conducted by Figueroa, Johnson (29) provides an excellent analysis of the 
relative preferences of various intervention components among key populations. Evidence suggests 
that oral fluid RDTs are marginally preferred over finger stick or whole blood tests, although this 
tends to vary across country income settings and population (29). For example, a recent UK study 
found that MSM preferred HIVST kits using a blood sample due to concerns around accuracy with 
oral fluid HIVST (31). In a study in Vietnam MSM and female sex workers (FSW) preferred oral fluid 
HIVSTs, while injection drug users (IDU) preferred blood based kits (25). In work from the US 
conducted with an ethnically diverse group of high risk MSM, more frequent testers preferred blood 
based testing, whereas men who tested less frequently preferred oral fluid HIVSTs (35). 
 Demonstrating impact of HIVST: outcomes from pilot projects and RCTs 
A range of feasibility studies, pilot projects and trials have provided data on the feasibility and 
impact of providing HIVST to different groups through an array of intervention designs. While the 
aims for each study vary (as does quality, particularly in feasibility and pilot studies), intervention 
designs tend to fall into one of two categories. The first is to detect longstanding prevalent infections 
among groups who have never tested or who test sub-optimally. The second is to increase frequency 
of testing to decrease the time between acquiring HIV infection and diagnosis, particularly in risk 
groups with high incidence. Evidence surrounding linkage to care in RCTs remains limited. Table two 
presents key RCTs planned, on-going and completed.  
 
Detection of prevalent infections  
Feasibility and pilot HIVST studies provide some evidence that HIVST will likely detect undiagnosed 
prevalent infections in individuals who test sub-optimally or have never tested, although it remains 
unclear if HIVST is more efficacious than other testing options to meet this aim. Projects in the US 
which focussed on reaching groups who have not previously tested or have difficulty accessing 
services seem to be successful in reaching MSM online (36, 37)  and to an extent in sex on premise 
venues (38). In Vietnam, community distribution was successful in reaching MSM, FSW and IDUs in 
urban and rural settings (25).  
Of particular interest is a cohort study conducted in Kenya which provided women with a varying 
number of HIVSTs to distribute to their sexual partners (39). Of 58 women recruited in antenatal 
care, 91% (53) distributed a kit to their partner, as did 86% (91) of 106 women in postpartum care 
and 75% (64) of 85 female sex workers (39). In an RCT distributing HIVSTs to pregnant women and 
their partners in Kenya, a significantly greater proportion of those in the HIVST arm tested for HIV 
compared to those randomised to SoC facility based testing. More male partners of women in the 
intervention group tested (90.8% vs 51.7%) and higher levels of couples testing also occurred in 
those in the intervention arm (75.4% vs 33.2%) (40). It is important to note that figures in both 
studies are based on participants’ reports of their partners’ testing behaviour and must therefore be 
interpreted with caution.  
 
Reducing interval between infection and diagnosis 
Efforts to increase the frequency with which at risk groups with high HIV incidence test are central to 
aspirations around the expansion of HIVST, and increased frequency of testing is a key benefit often 
repeated in values and preferences studies conducted with key populations. Non-RCT projects which 
have provided participants with a number of HIVSTs with instructions to test frequently have shown 
that distribution in line with this intervention approach is feasible amongst trans gender women in 
San Francisco (32), and MSM in Brazil and Peru (21).  
RCT evidence in this area is not strong, largely because studies have been underpowered to assess 
rates of diagnosis and therefore frequency of testing has been used as a proxy measure. In Seattle, 
MSM tested significantly more frequently when provided with multiple HIVSTs compared to SoC (5.3 
tests compared with 3.6 over 15 months) (41). The study was too small (n=230) to show an effect on 
increasing HIV diagnosis (41). These findings were repeated in MSM in Australia which showed 
increased testing frequency among the self-testing group, which did not reduce attendance in STI 
clinics indicating that men in this study used HIVST largely as a supplementary option (42). 
Encouragingly, in both these RCTs testing frequency was increased in both frequent and infrequent 
testers.  
 
Linkage to care 
Linkage to care for confirmatory testing is critical following a reactive result from a HIVST. A cluster 
randomised trial in Malawi reported that 56.3% (524/930) of people who had a reactive HIVST 
subsequently linked to care for confirmatory testing (43). Similar results have been seen in other 
observational studies in sub Saharan Africa (39). There is as yet very limited evidence from high 
income settings of linkage rates after HIVST, though a planned trial as detailed below, aims to 
provide data in this area.  
 
Planned studies  
Two planned studies are worth noting. The HIV Self-Testing Africa Project – Research (STAR project) 
is a $23 million four-year study taking place in Malawi, Zambia and Zimbabwe which will be the 
largest investigation of HIVST to date. This project will evaluate accuracy, uptake, case finding and 
linkage to care through a variety of models of HIVST delivery in these three countries.  
The planned SELPHI study in the UK will be the first RCT which attempts to address questions on 
both the ability of HIVST to detect prevalent infections and also to reduce the time between 
infection and diagnosis and aims to recruit 10 000 MSM in England and Wales from early 2017. The 
primary outcome is rates of HIV diagnosis as determined through confirmatory testing and linkage to 
care. This RCT will provide vital evidence for future policy makers in high-income settings and those 
working with key populations on the efficacy and cost effectiveness of HIVST in increasing rates of 
HIV diagnosis. 
Technological issues: Sensitivity of HIVST, particularly in early HIV infection 
Reliable use of HIVST kits has been reported as highly variable in observed studies (25-99.2%) (18, 
44, 45), though groups used in these studies are not necessarily reflective of those likely to need or 
use HIVST, which makes critical assessment of these results complex. However sensitivity and 
specificity estimates for HIVST when used by self-testers are high, though would appear to be higher 
for whole blood based HIVST compared to oral fluid based tests (96.2-100% compared to 80-100%) 
(46). Promisingly, repeated exposure to and use of HIVST seems to increase the confidence and 
ability of individuals to perform the tests correctly (19, 23, 47).  
Perhaps a more pressing concern, reflected by policy makers, commissioners and patients, is that 
HIVST kits have a lower sensitivity (and specificity) than those currently available in clinical settings, 
in particular in the period of early HIV infection known as the window period. The time from initial 
HIV infection to detection of infection (window period) depends on the properties of the test 
used. Figure 1 demonstrates the range of window periods before detection of HIV infection 
depending on whether antibody, antibody/antigen combination or HIV RNA tests are used.  
Currently available HIVST products are classed as second generation tests (antibody tests that 
are not laboratory run through tests), highlighting that HIVST is an innovation using older 
generation assays.  
Manufacturers of current blood based and oral test fluid based HIVST give window periods of up 
to 3 months for their products. OraquickTM also reports data indicating 95-98% detection of new 
HIV infection at 6 weeks and 99% by week 12 (48). Blood based antibody tests are likely to have 
slightly shorter window periods. In high risk populations the window period of current tests is 
particularly troubling, with mathematical modeling suggesting that widespread use of oral HIVST 
in high risk populations could potentially increase prevalence due to the long window period 
prior to detection of infection, and potentially a false sense of security from non-reactive HIVST 
results leading to greater sexual risk-taking (49).   
One of the potential utilities of HIVST is for those who require frequent HIV testing such as 
people taking PrEP. There is concern however that using an oral based HIVST in particular may 
lead to an increased rate of false negative tests in early infection. During the Bangkok Tenofovir 
Study, staff reported non-reactive monthly oral fluid HIVST (OraquickTM) results for 8 
participants (20% of all seroconversions in the study) for more than 3 months (84 days) after HIV 
infection. Participants receiving Tenofovir in this study took longer to develop a reactive 
OraQuickTM HIVST (191.8 days) than participants receiving placebo (16.8 days) (p = 0.02) (50). This 
may be due to the fact that the OraQuickTM test contains only a single glycoprotein antigen (anti-
gp41), so it will not identify HIV-infected individuals who fail to mount a substantial antibody 
response to that particular antigen, perhaps due to the presence of ART. It is likely however that 
HIVST kits, particularly blood based products, will improve in time with antigen detection, thus 
increasing sensitivity and specificity. 
 
Potential for social harms from HIVST 
When considering implementation of HIVST the potential for harm among the self-tester and the 
broader population are often iterated concerns.  A systematic review in 2014 of a variety of self-
diagnostics (including 49 papers on HIVST) found very little evidence of any harm occurring in self-
testing (51) . However ongoing vigilance is required for any potential negative effects as HIVST is 
expanded in at risk populations.  
A further concern around HIVST remains is the potential for intimate partner violence (IPV) and 
coercive testing though there is little current evidence in this area. In a recent study involving 600 
women in Kenya in which pregnant women were given HIVSTs for themselves and their partner; low 
and equal rates of IPV was observed in both the HIVST and SoC arms (1 incident in each) (40). 
However women who felt they were at risk of IPV were excluded from this study. Coercive testing 
has been described in Malawi, with more men than women reporting having been coerced (33, 52), 
but evidence suggests that this did not impact on intervention acceptability. In some cases coercion 
was felt to be beneficial in that it reduced personal barriers to testing indicating that ‘coercion’ 
conceptually must be understood in the social context within which it occurs (33).  
 
Further avenues of exploration: economic evaluation 
Evidence that HIVST will save costs to health services is currently lacking, particularly in resource rich 
settings though planned studies aim to fill this gap.  
In sub-Saharan Africa, in a sub-study from the cluster RCT in Malawi, the mean society cost of HIVST 
compared with facility based testing has been estimated to be US$9.2 (95% CI: US$9.1-US$9.3) 
versus US$11.8 (95 % CI: US$10.8-12.9). The cost per infection detected was higher through HIVST 
(US$97.5) than for facilities, which ranged between US$25.2-US$76.1 (53).  
Recently published evidence from Cambiano, Ford (54) assessed the potential impact and cost-
effectiveness of HIVST in Zimbabwe estimating two models where HIVST was not introduced, and 
one where it was. They estimated that the introduction of HIVST alongside existing testing 
interventions would save $75 million while averting 7000 disability-adjusted life-years over 20 years. 
This work also found however that should linkage to cascades of care be significantly impacted, ART 
CD4 thresholds lowered or if HIVSTs cost significantly more than the scenario estimated cost of $3 
then scenarios could emerge where HIVST was not cost effective when compared to the reference 
scenario. 
 
Conclusions 
Based on a review of the current of evidence HIVST is clearly acceptable and feasible to deliver to a 
range of populations in a variety of settings. In addition, HIVST has a role alongside other existing 
service provision, but it’s imperative to understand this in particular demographic, cultural and 
health systems contexts as well as the values and preferences of the intended end users. While 
HIVST seems able to encourage testing in  individuals who test sub-optimally and can increase the 
frequency at which some individuals test, it is less clear whether it is more efficacious or cost 
effective at detecting prevalent infections or reducing the interval between HIV infection and 
diagnosis for those in high incidence groups than current testing provision. Rates of linkage to care, 
an essential step following a reactive result with HIVST, are unclear particularily in resource rich 
settings.   
 
Improvements in kit sensitivity with shorter window periods, potentially with Ab/Ag combinations 
are vital to serve the needs of individuals particularily those from key populations with high 
incidence of infection. It is presently uncertain to what degree harms, if any, occur from HIVST and 
what form these harms may take. Social sciences should be key in responding to questions about 
harms so that these are understood from the perspective of those utilising the intervention. 
Economic evaluation of HIVST is in nascent stages and should be a key priority area moving forward. 
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Figure 1: Window of Detection for HIV, Based on the Test Used 
 
Legend: Nucleic acid amplification testing (NAAT) is performed to detect HIV RNA. Enzyme 
immunoassay (EIA) is performed to detect HIV antibody (second- and third-generation EIA) or HIV 
antibody/antigen (fourth-generation EIA). 
 
 
Note: Figure was reproduced from ‘Diagnosis and Management of Acute HIV Infection’. This material 
was accessed on [16/09/2016] on the HIV Clinical Resource website (www.hivguidelines.org). The HIV 
Clinical Guidelines Program is a collaborative effort of the New York State Department of Health AIDS 
Institute and the Johns Hopkins University Division of Infectious Diseases. 
 
  
  
Table 1: HIV testing intervention types 
Voluntary testing and counselling: Facility-based HIV testing and 
counselling. 
Community based HIV testing: Voluntary testing and counselling 
undertaken in a community setting such as in a van or in a 
commercial venue.  
Home-based voluntary testing and counselling: Testing 
undertaken in a domestic setting by a trained healthcare worker.  
HIV self-sampling: HIV testing whereby an individual takes their 
own sample and returns it to a lab which processes it and returns a 
result.  
HIV self-testing (HIVST): Testing where a person carries out an HIV 
rapid test on themselves. They take their own sample, process is 
and interpret their own result.  
Supervised HIV self-testing: HIVST conducted in the presence of a 
healthcare worker.  
 
  
Table 3: Completed, ongoing and planned HIVST RCTs. 
Investigator Year Population/ 
location 
HIVST kit Study Design Outcomes 
LSHTM, UNITAID/PSI, UCL, 
LSTM, CRP, WHO. HIV Self-
testing Africa (STAR).  Multiple 
studies planned. 
2016-18 General 
population, 
Malawi 
OraQuick Cluster Randomized Trial to 
SOC or HIVST or HIVST+ 
home HIV care initiation 
(n=5000) 
Uptake of testing in each group 
[12 mths]. Disclosure of a positive HIV result. 
ART initiation rates 
MacPherson, Corbett, Choko, 
Wellcome Trust. (43) 
2010-
2012 
General 
population, 
Malawi 
OraQuick Cluster Randomized Trial 
community areas (n=14, pop 
16, 660) to facility-based HIV 
care or home  HIV care. HIV-
ST promoted in all clusters.  
Uptake HIV-ST high (76%), 75.8% shared results 
with counselors.  
Positive HIVST reporting to CHW was higher in 
home HIV care cluster compared to facility (6%  
vs 3.3%) as was ART initiation  (2.2% vs 0.7%) 
Merchant et al, Rhode Island 
Hospital 
2015-16 Young Adult 
MSM  Rhode 
Island, US 
OraQuick Randomized to ST or blood 
based SS or standard  of 
care (n=450 total) 
Uptake of testing in each group 
[12 mths] 
MacGowan et al. The  eSTAMP 
Study, CDC/Emory 
2015-16 Internet-
recruited MSM, 
US 
OraQuick & 
Sure Check  
Randomized to 4 ST (2 oral, 
2 blood) or standard  of care 
(n=3200 total) 
Frequency of testing (12 mths). Linkage to care. 
Risk behaviour. Testing of partners and social 
networks 
The FORTH  Study, Kirby 
Institute, Australia (42) 
2013-15 MSM, Australia OraQuick Randomized to 4 ST (all  
oral) or standard  of care  
Frequency of testing (12 months).  STI test 
frequency, acceptability, use of tests 
(n=350) 
Thirumurthy, et al. University of 
North Carolina, Chapel Hill (40).  
 June – 
October 
2015 
Women in ANC 
or PPC in 
Kisumu, Kenya 
OraQuick Randomised to receive 2 
HIVSTs or a referral voucher 
to attend testing in VCT 
clinic.  
Male partner testing: 148 (51.7%) in SoC vs 
(90.8%) of HIVST group. Difference 39.1 (ci 32.4 
to 45.8) 
Couples testing: 95 (33.2%) in SoC vs 214 
(75.4%) HIVST. Difference 42.1 (34.7 to 49.6).  
Disclosure 145 (50.7) in SoC vs 255 (89.8) HIVST 
diff 39.1 (32.3 to 45.9) 
1 case of IPV in each arm (women who felt at 
risk of IPV were excluded).  
Stekler & Katz, University of 
Washington (NIH). The iTest 
Study (41) 
2012-14 MSM, Seattle, 
US 
OraQuick Randomized to ST (any 
number)  or standard  of 
care  (n=230) 
Number of HIV tests during follow-up (15 mth): 
5.3 ST versus 3.6.  STI diagnosis (5%  ST versus 
12%). CL AI at 12 months (21% ST versus 22%) 
and 15 months (29% ST versus 24%) 
Rodger et al, SELPHI study 2017-
2020 
MSM, England 
and Wales, UK 
BioSure Randomisation A: from 10 
000 MSM, 40% SoC, 60% 
one HIVST 
Randomisation B: 3 000 
eligible MSM. 50% receive 
SoC, 50% receive HIVST 
every 3 months.  
Primary outcome: diagnosis of HIV infection 
confirmed through linkage to UK national HIV 
surveillance database of all diagnosed 
infections. Secondary outcomes include HIV 
and STI testing behaviours, sexual activity and 
cost effectiveness of HIV ST in increasing HIV 
diagnosis. 
 
